style: 移除 Tab 导航和卡片内部左右 padding
- TabNavigation/SubTabContainer: 移除左侧 padding (pl=0) - BusinessStructureCard/BusinessSegmentsCard: 移除 CardBody 左右 padding - BusinessTreeItem: 黑金主题样式优化 🤖 Generated with [Claude Code](https://claude.com/claude-code) Co-Authored-By: Claude <noreply@anthropic.com>
This commit is contained in:
zdl
@@ -473,147 +473,65 @@ export const PINGAN_BANK_DATA = {
|
||||
},
|
||||
business_structure: [
|
||||
{
|
||||
business_name: '零售金融',
|
||||
business_name: '舒泰清（复方聚乙二醇电解质散IV）',
|
||||
business_level: 1,
|
||||
revenue: 812300,
|
||||
revenue: 17900,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 50.1,
|
||||
gross_margin: 42.5
|
||||
revenue_ratio: 55.16,
|
||||
gross_margin: 78.21
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: 11.2
|
||||
revenue_growth: -8.20
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
report_period: '2024年报'
|
||||
},
|
||||
{
|
||||
business_name: '信用卡业务',
|
||||
business_level: 2,
|
||||
revenue: 325000,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 20.1,
|
||||
gross_margin: 38.2
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: 15.8
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
},
|
||||
{
|
||||
business_name: '财富管理',
|
||||
business_level: 2,
|
||||
revenue: 280500,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 17.3,
|
||||
gross_margin: 52.1
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: 22.5
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
},
|
||||
{
|
||||
business_name: '消费信贷',
|
||||
business_level: 2,
|
||||
revenue: 206800,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 12.7,
|
||||
gross_margin: 35.8
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: 8.6
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
},
|
||||
{
|
||||
business_name: '对公金融',
|
||||
business_name: '苏肽生（注射用鼠神经生长因子）',
|
||||
business_level: 1,
|
||||
revenue: 685400,
|
||||
revenue: 13400,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 42.2,
|
||||
gross_margin: 38.6
|
||||
revenue_ratio: 41.21,
|
||||
gross_margin: 89.11
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: 6.8
|
||||
revenue_growth: -17.30
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
report_period: '2024年报'
|
||||
},
|
||||
{
|
||||
business_name: '公司贷款',
|
||||
business_level: 2,
|
||||
revenue: 412000,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 25.4,
|
||||
gross_margin: 36.2
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: 5.2
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
},
|
||||
{
|
||||
business_name: '供应链金融',
|
||||
business_level: 2,
|
||||
revenue: 185600,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 11.4,
|
||||
gross_margin: 41.5
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: 18.3
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
},
|
||||
{
|
||||
business_name: '投资银行',
|
||||
business_level: 2,
|
||||
revenue: 87800,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 5.4,
|
||||
gross_margin: 45.2
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: -2.3
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
},
|
||||
{
|
||||
business_name: '资金同业',
|
||||
business_name: '舒斯通（复方聚乙二醇(3350)电解质散）',
|
||||
business_level: 1,
|
||||
revenue: 125800,
|
||||
revenue: 771,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 7.7,
|
||||
gross_margin: 28.2
|
||||
revenue_ratio: 2.37
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: 3.5
|
||||
report_period: '2024年报'
|
||||
},
|
||||
{
|
||||
business_name: '阿司匹林肠溶片',
|
||||
business_level: 1,
|
||||
revenue: 396,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 1.22
|
||||
},
|
||||
report_period: '2024Q3'
|
||||
report_period: '2024年报'
|
||||
},
|
||||
{
|
||||
business_name: '研发业务',
|
||||
business_level: 1,
|
||||
report_period: '2024年报'
|
||||
}
|
||||
],
|
||||
business_segments: [
|
||||
{
|
||||
segment_name: '信用卡业务',
|
||||
description: '国内领先的信用卡发卡银行，流通卡量超7000万张',
|
||||
key_metrics: { cards_issued: 7200, transaction_volume: 28500, market_share: 8.5 }
|
||||
},
|
||||
{
|
||||
segment_name: '财富管理',
|
||||
description: '私人银行及财富管理业务快速发展，AUM突破4万亿',
|
||||
key_metrics: { aum: 42000, private_banking_customers: 125000, wealth_customers: 1200000 }
|
||||
},
|
||||
{
|
||||
segment_name: '供应链金融',
|
||||
description: '依托科技平台打造智慧供应链金融生态',
|
||||
key_metrics: { platform_customers: 35000, financing_balance: 5600, digitization_rate: 95 }
|
||||
segment_name: '已上市药品营销',
|
||||
segment_description: '舒泰神已上市药品营销业务主要包括舒泰清(复方聚乙二醇电解质散IV)和苏肽生(注射用鼠神经生长因子)两大核心产品。2024年实现营业收入3.25亿元，其中舒泰清贡献1.79亿元(55.16%)，苏肽生贡献1.34亿元(41.21%)。尽管面临市场竞争压力，产品毛利率保持高位，综合毛利率达80.83%，其中苏肽生毛利率高达89.11%。',
|
||||
competitive_position: '舒泰清为《中国消化内镜诊疗肠道准备指南》和《慢性便秘诊治指南》一线用药，苏肽生是国内首个国药准字鼠神经生长因子产品。公司医保目录产品舒斯通已落地，并布局舒亦清、舒常轻等系列产品形成梯队，构建了一定市场竞争优势。然而，2024年集采中同类(III型)产品中选，对舒泰清(IV型)形成潜在价格压力。',
|
||||
future_potential: '公司正在构建系列化产品线应对市场变化，研发投入保持高强度(1.62亿元，占营收49.97%)。在研管线中，STSP-0601血友病药物获FDA孤儿药资格，BDB-001被纳入突破性治疗品种，创新药研发持续推进。国家政策支持创新药发展，行业环境向好，同时国际化布局已有初步进展，未来3-5年有望通过新产品上市实现业绩突破。'
|
||||
}
|
||||
]
|
||||
},
|
||||
@@ -1336,11 +1254,68 @@ export const generateCompanyData = (stockCode, stockName = '示例公司') => {
|
||||
}
|
||||
},
|
||||
business_structure: [
|
||||
{ business_name: '核心产品', revenue: baseRevenue * 0.6, ratio: 60, growth: 12.5, report_period: '2024Q3' },
|
||||
{ business_name: '增值服务', revenue: baseRevenue * 0.25, ratio: 25, growth: 18.2, report_period: '2024Q3' },
|
||||
{ business_name: '其他业务', revenue: baseRevenue * 0.15, ratio: 15, growth: 5.8, report_period: '2024Q3' }
|
||||
{
|
||||
business_name: '舒泰清（复方聚乙二醇电解质散IV）',
|
||||
business_level: 1,
|
||||
revenue: 17900,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 55.16,
|
||||
gross_margin: 78.21
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: -8.20
|
||||
},
|
||||
report_period: '2024年报'
|
||||
},
|
||||
{
|
||||
business_name: '苏肽生（注射用鼠神经生长因子）',
|
||||
business_level: 1,
|
||||
revenue: 13400,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 41.21,
|
||||
gross_margin: 89.11
|
||||
},
|
||||
growth_metrics: {
|
||||
revenue_growth: -17.30
|
||||
},
|
||||
report_period: '2024年报'
|
||||
},
|
||||
{
|
||||
business_name: '舒斯通（复方聚乙二醇(3350)电解质散）',
|
||||
business_level: 1,
|
||||
revenue: 771,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 2.37
|
||||
},
|
||||
report_period: '2024年报'
|
||||
},
|
||||
{
|
||||
business_name: '阿司匹林肠溶片',
|
||||
business_level: 1,
|
||||
revenue: 396,
|
||||
revenue_unit: '万元',
|
||||
financial_metrics: {
|
||||
revenue_ratio: 1.22
|
||||
},
|
||||
report_period: '2024年报'
|
||||
},
|
||||
{
|
||||
business_name: '研发业务',
|
||||
business_level: 1,
|
||||
report_period: '2024年报'
|
||||
}
|
||||
],
|
||||
business_segments: []
|
||||
business_segments: [
|
||||
{
|
||||
segment_name: '已上市药品营销',
|
||||
segment_description: '舒泰神已上市药品营销业务主要包括舒泰清(复方聚乙二醇电解质散IV)和苏肽生(注射用鼠神经生长因子)两大核心产品。2024年实现营业收入3.25亿元，其中舒泰清贡献1.79亿元(55.16%)，苏肽生贡献1.34亿元(41.21%)。尽管面临市场竞争压力，产品毛利率保持高位，综合毛利率达80.83%，其中苏肽生毛利率高达89.11%。',
|
||||
competitive_position: '舒泰清为《中国消化内镜诊疗肠道准备指南》和《慢性便秘诊治指南》一线用药，苏肽生是国内首个国药准字鼠神经生长因子产品。公司医保目录产品舒斯通已落地，并布局舒亦清、舒常轻等系列产品形成梯队，构建了一定市场竞争优势。然而，2024年集采中同类(III型)产品中选，对舒泰清(IV型)形成潜在价格压力。',
|
||||
future_potential: '公司正在构建系列化产品线应对市场变化，研发投入保持高强度(1.62亿元，占营收49.97%)。在研管线中，STSP-0601血友病药物获FDA孤儿药资格，BDB-001被纳入突破性治疗品种，创新药研发持续推进。国家政策支持创新药发展，行业环境向好，同时国际化布局已有初步进展，未来3-5年有望通过新产品上市实现业绩突破。'
|
||||
}
|
||||
]
|
||||
},
|
||||
valueChainAnalysis: {
|
||||
value_chain_flows: [
|
||||
|
||||
Reference in New Issue
Block a user